Status: Enrolling by invitation,
Condition Summary: Thyroid-Associated Ophthalmopathy
Candidates’ Drug-Price Plans may Miss the Mark
(MedPage Today) — Tradeoffs must be made, experts say
Intravitreal diclofenac may improve visual acuity in eyes with macular edema due to BRVO
Intravitreal diclofenac may improve best corrected visual acuity and decrease central macular thickness in eyes with macular edema related to branch retinal vein occlusion, a study found.In the prospective study, 15 eyes of 15 patients received a single 500 µg/0.1 mL intravitreal dose of diclofenac injected with a 27-gauge needle in the inferotemporal quadrant 3.5 mm posterior to the limbus in pseudophakic eyes and 4 mm posterior to the limbus in phakic eyes.
Patient Awareness of Emergency Eye Problems Is Low
Serious eye problems like retinal detachment can come on suddenly and require immediate care, but few people are aware of these conditions, much less how they’re treated, a small U.S. study finds. Reuters Health Information
Senate bill focuses on development of genetically targeted drugs
The U.S. Senate is considering a bipartisan bill intended to speed up the development of genetically targeted drugs for patients with rare life-threatening or debilitating conditions.The Advancing Targeted Therapies for Rare Diseases Act of 2015 (S. 2030) would “allow the sponsor of an application for the approval of a targeted drug to rely upon data and information with respect to such sponsor’s previously approved targeted drugs.”
Senate bill focuses on development of genetically targeted drugs
The U.S. Senate is considering a bipartisan bill intended to speed up the development of genetically targeted drugs for patients with rare life-threatening or debilitating conditions.The Advancing Targeted Therapies for Rare Diseases Act of 2015 (S. 2030) would “allow the sponsor of an application for the approval of a targeted drug to rely upon data and information with respect to such sponsor’s previously approved targeted drugs.”